Russia’s New Corporate Perk: Ozempic for Employees to Boost Bottom Lines

A recent study from the Positsiya center reveals that businesses are considering adding weight-loss medications like Ozempic and Mounjaro to their insurance packages. While these drugs aren't officially sold in the country, the local market is flooded with at least 17 semaglutide and four tirzepatide clones. The logic is purely mechanical: HR managers believe that thinner employees are more productive, cost less in healthcare premiums, and are easier to keep around.

Employees seem to be biting, with 40% claiming they’d love to see these shots in their benefit plans. In fact, a significant portion of the workforce is ready to trade away traditional office parties or even their gym memberships just to get their hands on these injections. Experts like Alyona Barredo suggest that shedding pounds could indeed boost cognitive energy, turning the office into a high-octane machine of focused, lean workers.

However, the transition isn't just about handing out pens. Medics are warning that without strict screenings, this could turn into a Wild West scenario where everyone is on the juice. Lyudmila Morozova cautions that a lack of proper medical oversight creates massive liability for employers. Furthermore, nutritionist Asiyat Khachirova notes that these drugs don't magically build healthy habits, and without proper professional support, employees might just lose muscle mass instead of fat, eventually leading to a rebound effect that leaves the company right back where it started.

This is the ultimate evolution of corporate control, where the employer doesn't just manage the working hours but literally engineers the metabolism of the workforce. It’s a fascinating, if slightly terrifying, glimpse into a world where your BMI is officially a KPI and the breakroom water cooler is replaced by an endocrinology clinic.

Source: Forbes